
Hedwig M Blommestein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5194047/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longâ€ŧerm Outcomes in Patients With Multiple Myeloma. HemaSphere, 2018, 2, e45.	2.7	38
2	A costâ€effectiveness analysis of realâ€world treatment for elderly patients with multiple myeloma using a full disease model. European Journal of Haematology, 2016, 96, 198-208.	2.2	33
3	A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. Pharmacoeconomics, 2015, 33, 551-560.	3.3	30
4	Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. Value in Health, 2017, 20, 627-636.	0.3	27
5	Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 1211-1221.	3.3	21
6	Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies. Medical Decision Making, 2021, 41, 439-452.	2.4	21
7	Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. Clinical Therapeutics, 2017, 39, 1221-1232.e4.	2.5	17
8	Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. European Journal of Surgical Oncology, 2019, 45, 825-831.	1.0	17
9	Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica, 2019, 104, 1026-1035.	3.5	17
10	Costâ€effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a populationâ€based study. European Journal of Haematology, 2014, 92, 398-406.	2.2	16
11	Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. International Journal of Technology Assessment in Health Care, 2021, 37, e62.	0.5	14
12	Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leukemia Research, 2016, 50, 37-45.	0.8	12
13	Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib?. Value in Health, 2014, 17, 245-253.	0.3	11
14	Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. JAMA Network Open, 2021, 4, e213497.	5.9	7
15	Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country. Pediatric Blood and Cancer, 2020, 67, e28588.	1.5	5
16	A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. Leukemia and Lymphoma, 2021, 62, 549-559.	1.3	5
17	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. Cancers, 2021, 13, 5606.	3.7	5
18	Secondâ€line treatment for acute graftâ€versusâ€host disease with mesenchymal stromal cells: A decision model. European Journal of Haematology, 2018, 101, 676-683.	2.2	4

#	Article	IF	CITATIONS
19	Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 2109-2110.	2.0	2
20	Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Pharmacoeconomics, 2016, 34, 23-31.	3.3	2
21	Variation in the utilization of medical devices across Germany, Italy, and the Netherlands: A multilevel approach. Health Economics (United Kingdom), 2022, 31, 135-156.	1.7	2
22	Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review. Cancers, 2022, 14, 2444.	3.7	2
23	Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. Value in Health, 2020, 23, 1497-1508.	0.3	1
24	Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands. Melanoma Research, 2021, 31, 249-257.	1.2	1
25	Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. Expert Review of Anticancer Therapy, 2021, 21, 1-12	2.4	1